dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Galián Gay, Laura |
dc.contributor.author | Escalona Silva, Roxana Andreina |
dc.contributor.author | Teixido Tura, Gisela |
dc.contributor.author | Casas Masnou, Guillem |
dc.contributor.author | Ferrer-Sistach, Elena |
dc.contributor.author | Mitroi, Cristina |
dc.contributor.author | González Alujas, Teresa |
dc.contributor.author | Gutierrez García-Moreno, Laura |
dc.contributor.author | Fernández Galera, Ruben |
dc.contributor.author | De Carvalho Negrao Valente, Filipa Xavier |
dc.contributor.author | Ruiz Muñoz, Aroa |
dc.contributor.author | Sao Aviles, Augusto Cesar |
dc.contributor.author | Rodríguez Palomares, Jose Fernando |
dc.contributor.author | Ferreira González, Ignacio |
dc.contributor.author | Evangelista Masip, Artur |
dc.contributor.author | Guala, Andrea |
dc.date.accessioned | 2022-09-12T10:03:38Z |
dc.date.available | 2022-09-12T10:03:38Z |
dc.date.issued | 2022-04-01 |
dc.identifier.citation | Galian-Gay L, Escalona Silva RA, Teixidó-Turà G, Casas G, Ferrer-Sistach E, Mitroi C, et al. Prognosis of Paradoxical Low-Flow Low-Gradient Aortic Stenosis: A Severe, Non-critical Form, With Surgical Treatment Benefits. Front Cardiovasc Med. 2022 Apr 1;9:852954. |
dc.identifier.issn | 2297-055X |
dc.identifier.uri | https://hdl.handle.net/11351/8157 |
dc.description | Aortic stenosis; Echocardiography; Heart valve disease |
dc.description.abstract | Objectives: To determine the risk of mortality and need for aortic valve replacement (AVR) in patients with low-flow low-gradient (LFLG) aortic stenosis (AS).
Methods: A longitudinal multicentre study including consecutive patients with severe AS (aortic valve area [AVA] < 1.0 cm2) and normal left ventricular ejection fraction (LVEF). Patients were classified as: high-gradient (HG, mean gradient ≥ 40 mmHg), normal-flow low-gradient (NFLG, mean gradient < 40 mmHg, indexed systolic volume (SVi) > 35 ml/m2) and LFLG (mean gradient < 40 mmHg, SVi ≤ 35 ml/m2).
Results: Of 1,391 patients, 147 (10.5%) had LFLG, 752 (54.1%) HG, and 492 (35.4%) NFLG. Echocardiographic parameters of the LFLG group showed similar AVA to the HG group but with less severity in the dimensionless index, calcification, and hypertrophy. The HG group required AVR earlier than NFLG (p < 0.001) and LFLG (p < 0.001), with no differences between LFLG and NFLG groups (p = 0.358). Overall mortality was 27.7% (CI 95% 25.3–30.1) with no differences among groups (p = 0.319). The impact of AVR in terms of overall mortality reduction was observed the most in patients with HG (hazard ratio [HR]: 0.17; 95% CI: 0.12–0.23; p < 0.001), followed by patients with LFLG (HR: 0.25; 95% CI: 0.13–0.49; p < 0.001), and finally patients with NFLG (HR: 0.29; 95% CI: 0.20–0.44; p < 0.001), with a risk reduction of 84, 75, and 71%, respectively.
Conclusions: Paradoxical LFLG AS affects 10.5% of severe AS, and has a lower need for AVR than the HG group and similar to the NFLG group, with no differences in mortality. AVR had a lower impact on LFLG AS compared with HG AS. Therefore, the findings of the present study showed LFLG AS to have an intermediate clinical risk profile between the HG and NFHG groups. |
dc.language.iso | eng |
dc.publisher | Frontiers Media |
dc.relation.ispartofseries | Frontiers in Cardiovascular Medicine;9 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Vàlvula aòrtica - Estenosi - Cirurgia |
dc.subject | Vàlvula aòrtica - Estenosi - Prognosi |
dc.subject.mesh | Aortic Valve Stenosis |
dc.subject.mesh | /surgery |
dc.subject.mesh | Prognosis |
dc.title | Prognosis of Paradoxical Low-Flow Low-Gradient Aortic Stenosis: A Severe, Non-critical Form, With Surgical Treatment Benefits |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3389/fcvm.2022.852954 |
dc.subject.decs | estenosis de la válvula aórtica |
dc.subject.decs | /cirugía |
dc.subject.decs | pronóstico |
dc.relation.publishversion | https://doi.org/10.3389/fcvm.2022.852954 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Galian-Gay L, Escalona Silva RA, Teixidó-Turà G, Casas G, González-Alujas T, Gutiérrez L, Fernandez-Galera R, Valente F, Guala A, Ruiz-Muñoz A, Avilés CAS, Palomares JFR, Ferreira I, Evangelista A] Servei de Cardiologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. CIBER-CV, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Ferrer-Sistach E] Department of Cardiology, Hospital Universitari Germans Tries i Pujol, Badalona, Spain. [Mitroi C] Department of Cardiology, Hospital Puerta de Hierro - Majadahonda, Madrid, Spain |
dc.identifier.pmid | 35433871 |
dc.identifier.wos | 000806264400001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |